NCT00449813: CONQUEST: pantoprazole and reflux symptoms

Medicine Signal Editorial Desk
Updated 2026-10-10

Registry status when checked 2026-10-10Terminated

Study: CONQUEST, a pantoprazole study of gastroesophageal reflux disease symptoms and their assessment, protocol BY1023/NL511. 1 2

Design and measurements: The phase IV record lists 40 actual participants receiving pantoprazole 40 mg daily for eight weeks. The key comparison concerned the physician's assessment of heartburn versus the patient's broader ReQuest symptom assessment, in people with a history of reflux symptoms. 1 2

What is established: The registry displays terminated status with a May 2012 update. No numerical agreement statistic, symptom-response rate, or reason for termination was verified. Because the comparison concerned assessment methods rather than pantoprazole versus a competing drug, this trial should not be used to claim drug superiority. 1 2

Sources

1. ClinicalTrials.gov — ClinicalTrials.gov — NCT00449813. Original study registration: sponsor, design, population, endpoints and dated history.Original study registration · Original record checked against the registry API. Checked 2026-10-10. Registration and current registry fields do not by themselves establish efficacy. Historical details in the article retain their stated date. Supplied note: ClinicalTrials.gov — NCT00449813. Original study registration: sponsor, design, population, endpoints and dated history.

2. ICH GCP — ICH GCP — readable reproduction of the sponsor-submitted ClinicalTrials.gov record. Supports the registration details quoted here; not an independent clinical-results publication.Cited supporting source · Link and description preserved from supplied research. Checked in supplied research dated 2026-10-10. Source description comes from supplied research; underlying page was not independently re-read for this update.